Dipeptidyl peptidase-4 inhibitors and incretin hormones represent a sophisticated approach to managing type 2 diabetes by enhancing the body's natural glucose regulation. Incretins—principally glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)—are gut hormones that stimulate insulin secretion in response to meals. However, these hormones are rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4). DPP-4 inhibitors, also known as gliptins, work by blocking this enzymatic breakdown, thereby prolonging incretin activity and improving glycaemic control with minimal risk of hypoglycaemia. This article explores how DPP-4 inhibitors interact with the incretin system, their clinical benefits, safety considerations, and their role within contemporary diabetes management aligned with NICE guidance.

What Are Incretins and How Do They Regulate Blood Sugar?

Incretins are naturally occurring hormones produced in the gastrointestinal tract that play a crucial role in glucose homeostasis. The two principal incretin hormones are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones are released in response to food intake, particularly following the ingestion of carbohydrates and fats, and are responsible for a significant portion of insulin secretion after meals.

The incretin effect accounts for approximately 50–70% of postprandial insulin secretion in healthy individuals. When nutrients enter the small intestine, specialised enteroendocrine cells release GLP-1 and GIP into the bloodstream. These hormones then travel to the pancreas, where they bind to specific receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion. This mechanism is particularly elegant because insulin release only occurs when blood glucose levels are elevated, thereby minimising the risk of hypoglycaemia.

Beyond insulin secretion, incretins exert several other beneficial metabolic effects. GLP-1 suppresses glucagon secretion from pancreatic alpha cells, which reduces hepatic glucose production. It also slows gastric emptying, prolonging the absorption of nutrients and promoting satiety, which may contribute to modest weight reduction.

In individuals with type 2 diabetes, the incretin effect is substantially diminished. Research demonstrates that the insulinotropic effect of GIP is markedly reduced, whilst the response to GLP-1 is relatively preserved, though GLP-1 secretion itself may be modestly reduced in some individuals. Furthermore, the enzyme dipeptidyl peptidase-4 (DPP-4) rapidly degrades incretin hormones within minutes of their release, with GLP-1 having a half-life of only 1–2 minutes. This rapid degradation significantly limits the therapeutic potential of endogenous incretins, creating the rationale for pharmacological interventions that either mimic or preserve incretin activity. It is important to note that whilst animal studies suggest potential protective effects on pancreatic beta cell mass, this has not been established in humans and is not a treatment goal for DPP-4 inhibitor therapy.

How Dipeptidyl Peptidase-4 Inhibitors Work with Incretins

Dipeptidyl peptidase-4 (DPP-4) inhibitors, also known as gliptins, represent an innovative approach to enhancing the body's natural incretin system. These medications work by selectively inhibiting the DPP-4 enzyme, which is responsible for the rapid degradation of GLP-1 and GIP. By blocking this enzymatic breakdown, DPP-4 inhibitors effectively prolong the active life of endogenous incretins, typically increasing their circulating concentrations by two- to threefold.

The mechanism of action is elegantly physiological. When a patient takes a DPP-4 inhibitor such as sitagliptin, vildagliptin, saxagliptin, linagliptin, or alogliptin, the medication binds to and inhibits the DPP-4 enzyme throughout the body. Following food intake, when incretin hormones are naturally released from the gut, they remain active in the circulation for considerably longer periods. This extended activity translates into enhanced glucose-dependent insulin secretion and more effective suppression of inappropriate glucagon release.

Crucially, because DPP-4 inhibitors work by amplifying the body's own glucose-dependent mechanisms, their glucose-lowering effect is inherently self-limiting. Insulin secretion only occurs when blood glucose is elevated, and the effect diminishes as glucose levels normalise. This glucose-dependent action explains why DPP-4 inhibitors carry a very low intrinsic risk of hypoglycaemia when used as monotherapy.

DPP-4 inhibitors are administered orally, typically once or twice daily depending on the specific agent. Linagliptin is unique among the class as it is primarily excreted via the bile rather than the kidneys, making it particularly suitable for patients with renal impairment without dose adjustment. Other agents in the class require dose reduction in moderate to severe chronic kidney disease. The medications are generally well-absorbed, with peak plasma concentrations achieved within 1–4 hours, and they demonstrate consistent pharmacokinetic profiles that support reliable glycaemic control throughout the day.

Important prescribing considerations: DPP-4 inhibitors are indicated only for type 2 diabetes and should not be used in type 1 diabetes or for the treatment of diabetic ketoacidosis. According to NICE guidance (NG28), DPP-4 inhibitors should not be prescribed in combination with GLP-1 receptor agonists, as both act on the incretin pathway and there is minimal additive benefit. Vildagliptin requires specific hepatic monitoring: baseline liver function tests (LFTs) should be performed before starting treatment, with periodic monitoring thereafter, and the medication should be avoided in patients with hepatic impairment. Treatment should be discontinued if alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceed three times the upper limit of normal, or if jaundice develops. Additionally, saxagliptin requires dose reduction when co-prescribed with strong CYP3A4/5 inhibitors such as ketoconazole or clarithromycin (consult the Summary of Product Characteristics for specific guidance).

Clinical Benefits of DPP-4 Inhibitors in Type 2 Diabetes

DPP-4 inhibitors provide meaningful glycaemic improvements in people with type 2 diabetes, typically reducing HbA1c by 0.5–1.0% (5–11 mmol/mol) when added to existing therapy or used as monotherapy. According to NICE guidance (NG28), DPP-4 inhibitors are recommended as second-line treatment options when metformin alone provides inadequate glycaemic control, or as first-line alternatives when metformin is contraindicated or not tolerated.

One of the most significant advantages of DPP-4 inhibitors is their weight-neutral profile. Unlike sulphonylureas, thiazolidinediones, and insulin, which are commonly associated with weight gain, DPP-4 inhibitors typically have minimal impact on body weight. This characteristic makes them particularly valuable for patients with type 2 diabetes who are overweight or obese, as weight gain can worsen insulin resistance and cardiovascular risk factors. Some patients may experience modest weight loss, though this is not a consistent finding across all studies.

The very low risk of hypoglycaemia represents another key clinical benefit. Large-scale clinical trials have consistently demonstrated that DPP-4 inhibitors, when used as monotherapy or in combination with metformin, carry hypoglycaemia rates comparable to placebo. This safety profile is especially important for elderly patients, those with irregular eating patterns, or individuals in occupations where hypoglycaemia poses significant risks. However, when combined with sulphonylureas or insulin, the risk of hypoglycaemia increases, and dose reduction of these agents may be necessary.

DPP-4 inhibitors offer convenient oral administration with generally once-daily dosing, which supports treatment adherence. They can be taken with or without food, and the tablets are typically small and easy to swallow. The medications are well-suited for use in various patient populations, including the elderly and those with mild to moderate renal impairment (with appropriate dose adjustments for most agents).

Cardiovascular safety: Large cardiovascular outcome trials (TECOS, SAVOR-TIMI 53, EXAMINE, CARMELINA, CAROLINA) have demonstrated that DPP-4 inhibitors are cardiovascularly safe, showing non-inferiority to placebo. However, it is important to note that DPP-4 inhibitors have no established cardiovascular or renal protective outcome benefits, unlike SGLT2 inhibitors or certain GLP-1 receptor agonists. The MHRA has issued specific safety advice regarding an increased risk of heart failure with saxagliptin and a possible signal with alogliptin. Healthcare professionals should consider these risks before prescribing saxagliptin or alogliptin, particularly in patients with existing cardiovascular disease or renal impairment. Patients should be monitored for signs and symptoms of heart failure (such as dyspnoea, peripheral oedema, or rapid weight gain), and the medication should be discontinued if heart failure develops.

Side Effects and Safety Considerations for DPP-4 Inhibitors

DPP-4 inhibitors are generally well-tolerated, with most adverse effects being mild and transient. The most commonly reported side effects include nasopharyngitis, upper respiratory tract infections, and headache, though these occur at rates similar to placebo in clinical trials. Gastrointestinal symptoms such as nausea, diarrhoea, and abdominal discomfort may occur but are considerably less frequent and severe than those associated with GLP-1 receptor agonists or metformin.

Pancreatitis has been identified as a rare but serious potential adverse effect. Post-marketing surveillance and observational studies have reported cases of acute pancreatitis in patients taking DPP-4 inhibitors, though establishing a definitive causal relationship remains challenging. The MHRA advises that patients should be informed about the characteristic symptoms of acute pancreatitis—persistent, severe abdominal pain—and instructed to discontinue treatment and seek immediate medical attention if these symptoms develop. Healthcare professionals should exercise caution when prescribing DPP-4 inhibitors to patients with a history of pancreatitis.

There have been reports of severe arthralgia (joint pain) associated with DPP-4 inhibitor use, with symptoms sometimes being disabling and resolving upon discontinuation. The onset can occur within days to years after starting treatment. If a patient develops severe, persistent joint pain whilst taking a DPP-4 inhibitor, discontinuation should be considered, particularly if symptoms significantly impair quality of life.

Hypersensitivity reactions, including angioedema, urticaria, and rare cases of anaphylaxis, have been reported. These reactions may occur within the first three months of treatment but can develop at any time. Patients with a history of angioedema with other medications should be prescribed DPP-4 inhibitors with caution. Bullous pemphigoid, a rare autoimmune blistering skin condition, has also been associated with DPP-4 inhibitor use, and patients presenting with persistent blistering skin lesions should discontinue treatment and be referred for dermatological assessment.

Heart failure risk: As noted above, the MHRA has issued specific warnings regarding an increased risk of heart failure with saxagliptin and a possible signal with alogliptin. Before prescribing these agents, healthcare professionals should carefully consider the risks, particularly in patients with existing cardiovascular disease or renal impairment. Patients should be monitored for signs and symptoms of heart failure, including unexplained dyspnoea, peripheral oedema, or rapid weight gain. If heart failure develops, the DPP-4 inhibitor should be discontinued.

Hepatic monitoring for vildagliptin: Vildagliptin requires baseline liver function tests (LFTs) before starting treatment, with periodic monitoring thereafter as recommended in the Summary of Product Characteristics. The medication should be avoided in patients with hepatic impairment. Treatment must be discontinued if ALT or AST levels exceed three times the upper limit of normal, or if jaundice or other signs of liver dysfunction develop.

For patients with renal impairment, dose adjustments are necessary for most DPP-4 inhibitors except linagliptin. Regular monitoring of renal function is recommended, particularly in elderly patients or those with progressive kidney disease. When used in combination with sulphonylureas or insulin, the dose of these agents may need reduction to minimise hypoglycaemia risk. Patients should be advised to maintain regular blood glucose monitoring and report any concerning symptoms to their GP or diabetes specialist nurse promptly.

Pregnancy and breastfeeding: DPP-4 inhibitors are generally not recommended during pregnancy or breastfeeding unless the potential benefit justifies the potential risk. Women of childbearing potential should discuss contraception and pregnancy planning with their healthcare team. Consult individual Summaries of Product Characteristics for agent-specific guidance.

Reporting adverse reactions: Patients and healthcare professionals are encouraged to report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. This helps to monitor the safety of medicines and contributes to ongoing pharmacovigilance.

Comparing DPP-4 Inhibitors with Other Diabetes Medications

When considering treatment options for type 2 diabetes, DPP-4 inhibitors occupy a distinct position within the therapeutic landscape, offering particular advantages and limitations compared with other glucose-lowering medications. Understanding these differences enables clinicians to make individualised treatment decisions aligned with NICE guidance and patient-specific factors.

Compared with sulphonylureas, DPP-4 inhibitors offer a significantly lower risk of hypoglycaemia and weight neutrality, whereas sulphonylureas commonly cause weight gain and carry substantial hypoglycaemia risk. However, sulphonylureas typically provide greater HbA1c reductions (1.0–1.5%) and are considerably less expensive. Sulphonylureas may be preferred when cost is a primary consideration and the patient can safely manage potential hypoglycaemia, whilst DPP-4 inhibitors suit patients where hypoglycaemia avoidance is paramount.

SGLT2 inhibitors (sodium-glucose co-transporter-2 inhibitors) offer comparable glycaemic efficacy to DPP-4 inhibitors but provide additional benefits including weight loss (typically 2–3 kg), blood pressure reduction, and proven cardiovascular and renal protection. NICE recommends SGLT2 inhibitors preferentially for patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease. It is important to note that SGLT2 inhibitors are not universally contraindicated in severe renal impairment; indeed, several agents (such as dapagliflozin) are now indicated at low estimated glomerular filtration rate (eGFR) specifically for their cardiorenal protective benefits, though their glucose-lowering effect diminishes at lower eGFR levels. Specific eGFR thresholds for initiation and continuation vary by agent and indication—consult NICE technology appraisals (e.g., TA775 for dapagliflozin in CKD, TA679 for dapagliflozin in heart failure with reduced ejection fraction) and individual Summaries of Product Characteristics. SGLT2 inhibitors carry risks of genital mycotic infections and diabetic ketoacidosis (particularly in insulin-deficient states). DPP-4 inhibitors may be preferred for patients unable to tolerate SGLT2 inhibitors or those with recurrent urogenital infections.

GLP-1 receptor agonists provide superior glycaemic control (HbA1c reductions of 1.0–1.5%), significant weight loss, and—for certain agents such as liraglutide, subcutaneous semaglutide, and dulaglutide—proven cardiovascular benefits including reduction in major adverse cardiovascular events. These advantages make GLP-1 receptor agonists increasingly favoured in contemporary guidelines. However, they require subcutaneous injection (except for oral semaglutide), commonly cause gastrointestinal side effects, and are substantially more expensive than DPP-4 inhibitors. For patients unwilling or unable to use injectable therapies, or those who cannot tolerate GLP-1 receptor agonist side effects, DPP-4 inhibitors represent a valuable oral alternative that modulates the same incretin pathway. Importantly, DPP-4 inhibitors should not be co-prescribed with GLP-1 receptor agonists, as both act on the incretin system and there is minimal additive benefit (per NICE NG28).

Compared with thiazolidinediones (pioglitazone), DPP-4 inhibitors avoid the risks of fluid retention, heart failure exacerbation, bone fractures, and weight gain associated with this class. Pioglitazone may offer more durable glycaemic control in some patients, and there is some evidence of cardiovascular benefit in specific populations, though this must be balanced against significant risks including fluid retention, heart failure, weight gain, and fractures. Consult the Summary of Product Characteristics and NICE guidance when considering pioglitazone.

Metformin remains the foundation of type 2 diabetes management, and DPP-4 inhibitors are commonly used in combination with metformin, providing complementary mechanisms of action. The choice between different second-line agents should consider individual patient characteristics, comorbidities (particularly cardiovascular disease, heart failure, and chronic kidney disease), treatment preferences, and cost-effectiveness, with shared decision-making central to optimising long-term outcomes.

Frequently Asked Questions